Structured Review

TriLink mrna molecules
Structure and characterization of lipopolyplex <t>mRNA</t> vaccine ( a ) Schematic view of the lipopolyplex mRNA vaccine. The vaccine is composed of a polyplex core assembled through electrostatic interaction between the positively charged <t>PbAE</t> polymer and the negatively charged mRNA molecule. The polyplex is encapsulated into a lipid shell. ( b ) Gel retardation assay on polyplex-mRNA binding. Samples were loaded in the following order: free mRNA, polyplex/mRNA with 10, 20, 30 and 40 (w/w). ( c–e ) TEM images of the empty liposomal shell (c), polyplex/mRNA core (w/w=20) (d), and lipopolyplex/mRNA core-shell structure (e). ( f–k ) eGFP expression in DC2.4 cells treated with mRNA-packaged particles. DC2.4 cells were treated with (f) PBS control, g) PbAE/eGFP mRNA core, h) EDOPC/DOPE-packaged PbAE/eGFP mRNA, i) DOTAP/Chol-packaged PbAE/eGFP mRNA, j) CHEMS/DOPE/R8-packaged PbAE/eGFP mRNA or k) protamine/eGFP mRNA core, and eGFP expression was detected under a fluorescent microscope 24 hours later. l) DC2.4 viability upon treatment with the different particles.
Mrna Molecules, supplied by TriLink, used in various techniques. Bioz Stars score: 91/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mrna molecules/product/TriLink
Average 91 stars, based on 2 article reviews
Price from $9.99 to $1999.99
mrna molecules - by Bioz Stars, 2020-09
91/100 stars

Images

1) Product Images from "Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination"

Article Title: Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination

Journal: Biomaterials

doi: 10.1016/j.biomaterials.2017.02.019

Structure and characterization of lipopolyplex mRNA vaccine ( a ) Schematic view of the lipopolyplex mRNA vaccine. The vaccine is composed of a polyplex core assembled through electrostatic interaction between the positively charged PbAE polymer and the negatively charged mRNA molecule. The polyplex is encapsulated into a lipid shell. ( b ) Gel retardation assay on polyplex-mRNA binding. Samples were loaded in the following order: free mRNA, polyplex/mRNA with 10, 20, 30 and 40 (w/w). ( c–e ) TEM images of the empty liposomal shell (c), polyplex/mRNA core (w/w=20) (d), and lipopolyplex/mRNA core-shell structure (e). ( f–k ) eGFP expression in DC2.4 cells treated with mRNA-packaged particles. DC2.4 cells were treated with (f) PBS control, g) PbAE/eGFP mRNA core, h) EDOPC/DOPE-packaged PbAE/eGFP mRNA, i) DOTAP/Chol-packaged PbAE/eGFP mRNA, j) CHEMS/DOPE/R8-packaged PbAE/eGFP mRNA or k) protamine/eGFP mRNA core, and eGFP expression was detected under a fluorescent microscope 24 hours later. l) DC2.4 viability upon treatment with the different particles.
Figure Legend Snippet: Structure and characterization of lipopolyplex mRNA vaccine ( a ) Schematic view of the lipopolyplex mRNA vaccine. The vaccine is composed of a polyplex core assembled through electrostatic interaction between the positively charged PbAE polymer and the negatively charged mRNA molecule. The polyplex is encapsulated into a lipid shell. ( b ) Gel retardation assay on polyplex-mRNA binding. Samples were loaded in the following order: free mRNA, polyplex/mRNA with 10, 20, 30 and 40 (w/w). ( c–e ) TEM images of the empty liposomal shell (c), polyplex/mRNA core (w/w=20) (d), and lipopolyplex/mRNA core-shell structure (e). ( f–k ) eGFP expression in DC2.4 cells treated with mRNA-packaged particles. DC2.4 cells were treated with (f) PBS control, g) PbAE/eGFP mRNA core, h) EDOPC/DOPE-packaged PbAE/eGFP mRNA, i) DOTAP/Chol-packaged PbAE/eGFP mRNA, j) CHEMS/DOPE/R8-packaged PbAE/eGFP mRNA or k) protamine/eGFP mRNA core, and eGFP expression was detected under a fluorescent microscope 24 hours later. l) DC2.4 viability upon treatment with the different particles.

Techniques Used: Electrophoretic Mobility Shift Assay, Binding Assay, Transmission Electron Microscopy, Expressing, Microscopy

2) Product Images from "Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination"

Article Title: Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination

Journal: Biomaterials

doi: 10.1016/j.biomaterials.2017.02.019

Stimulation of DC antigen cross-presentation by the LPP/mRNA vaccine a ) Flow cytometry analysis on H-2k b -OVA 257–264 presentation. b ) Time-dependent IL-2 secretion by OVA-specific CD4 + and CD8 + T cells after co-incubation with post-treated BMDCs. B3Z: OVA-specific CD8 + T cell; DOBW: OVA-specific CD4 + T cell. c ) Time-dependent IL-2 secretion by OVA-specific CD4 + and CD8 + T cells after co-incubation with post-treated DC2.4 cells. d ) Comparison of IL-2 secretion by OVA-specific CD8 + T cells after co-incubation with DC2.4 cells pretreated with LPP/OVA mRNA or LPP/OVA protein.
Figure Legend Snippet: Stimulation of DC antigen cross-presentation by the LPP/mRNA vaccine a ) Flow cytometry analysis on H-2k b -OVA 257–264 presentation. b ) Time-dependent IL-2 secretion by OVA-specific CD4 + and CD8 + T cells after co-incubation with post-treated BMDCs. B3Z: OVA-specific CD8 + T cell; DOBW: OVA-specific CD4 + T cell. c ) Time-dependent IL-2 secretion by OVA-specific CD4 + and CD8 + T cells after co-incubation with post-treated DC2.4 cells. d ) Comparison of IL-2 secretion by OVA-specific CD8 + T cells after co-incubation with DC2.4 cells pretreated with LPP/OVA mRNA or LPP/OVA protein.

Techniques Used: Flow Cytometry, Cytometry, Incubation

Preferential uptake of the lipopolyplex mRNA vaccine by dendritic cells (a) Flow cytometry analysis on GFP-positive cells after DC2.4, MDA-MB-231 and mDMEC cells were incubated with lipopolyplex/eGFP mRNA for 24 hours. (b) Bioluminescent image to detect luciferase expression in mice 48 hours after s.c. injection of LPP/Luc. Left: control mouse; right: LPP/Luc-treated mouse.
Figure Legend Snippet: Preferential uptake of the lipopolyplex mRNA vaccine by dendritic cells (a) Flow cytometry analysis on GFP-positive cells after DC2.4, MDA-MB-231 and mDMEC cells were incubated with lipopolyplex/eGFP mRNA for 24 hours. (b) Bioluminescent image to detect luciferase expression in mice 48 hours after s.c. injection of LPP/Luc. Left: control mouse; right: LPP/Luc-treated mouse.

Techniques Used: Flow Cytometry, Cytometry, Multiple Displacement Amplification, Incubation, Luciferase, Expressing, Mouse Assay, Injection

Mechanism of cell entry ( a – h ) Images of DC2.4 cells treated with LPP/0.5 μg FAM-labeled eGFP mRNA for 4 hours in presence of (a) mock control, (b) amiloride, (c) chlorpromazine, (d) chloroquine, (e) genistein, (f) pimozide, (g) nocodazole, and (h) cytochalasin D. ( i ) Image J analysis on FAM-positive cells. ( j ) Time-dependent uptake of LPP/FAM-labeled eGFP mRNA by DC2.4 cells. Error bars represent the mean ± standard deviation of triplicate experiments.
Figure Legend Snippet: Mechanism of cell entry ( a – h ) Images of DC2.4 cells treated with LPP/0.5 μg FAM-labeled eGFP mRNA for 4 hours in presence of (a) mock control, (b) amiloride, (c) chlorpromazine, (d) chloroquine, (e) genistein, (f) pimozide, (g) nocodazole, and (h) cytochalasin D. ( i ) Image J analysis on FAM-positive cells. ( j ) Time-dependent uptake of LPP/FAM-labeled eGFP mRNA by DC2.4 cells. Error bars represent the mean ± standard deviation of triplicate experiments.

Techniques Used: Labeling, Standard Deviation

Structure and characterization of lipopolyplex mRNA vaccine ( a ) Schematic view of the lipopolyplex mRNA vaccine. The vaccine is composed of a polyplex core assembled through electrostatic interaction between the positively charged PbAE polymer and the negatively charged mRNA molecule. The polyplex is encapsulated into a lipid shell. ( b ) Gel retardation assay on polyplex-mRNA binding. Samples were loaded in the following order: free mRNA, polyplex/mRNA with 10, 20, 30 and 40 (w/w). ( c–e ) TEM images of the empty liposomal shell (c), polyplex/mRNA core (w/w=20) (d), and lipopolyplex/mRNA core-shell structure (e). ( f–k ) eGFP expression in DC2.4 cells treated with mRNA-packaged particles. DC2.4 cells were treated with (f) PBS control, g) PbAE/eGFP mRNA core, h) EDOPC/DOPE-packaged PbAE/eGFP mRNA, i) DOTAP/Chol-packaged PbAE/eGFP mRNA, j) CHEMS/DOPE/R8-packaged PbAE/eGFP mRNA or k) protamine/eGFP mRNA core, and eGFP expression was detected under a fluorescent microscope 24 hours later. l) DC2.4 viability upon treatment with the different particles.
Figure Legend Snippet: Structure and characterization of lipopolyplex mRNA vaccine ( a ) Schematic view of the lipopolyplex mRNA vaccine. The vaccine is composed of a polyplex core assembled through electrostatic interaction between the positively charged PbAE polymer and the negatively charged mRNA molecule. The polyplex is encapsulated into a lipid shell. ( b ) Gel retardation assay on polyplex-mRNA binding. Samples were loaded in the following order: free mRNA, polyplex/mRNA with 10, 20, 30 and 40 (w/w). ( c–e ) TEM images of the empty liposomal shell (c), polyplex/mRNA core (w/w=20) (d), and lipopolyplex/mRNA core-shell structure (e). ( f–k ) eGFP expression in DC2.4 cells treated with mRNA-packaged particles. DC2.4 cells were treated with (f) PBS control, g) PbAE/eGFP mRNA core, h) EDOPC/DOPE-packaged PbAE/eGFP mRNA, i) DOTAP/Chol-packaged PbAE/eGFP mRNA, j) CHEMS/DOPE/R8-packaged PbAE/eGFP mRNA or k) protamine/eGFP mRNA core, and eGFP expression was detected under a fluorescent microscope 24 hours later. l) DC2.4 viability upon treatment with the different particles.

Techniques Used: Electrophoretic Mobility Shift Assay, Binding Assay, Transmission Electron Microscopy, Expressing, Microscopy

Related Articles

Incubation:

Article Title: Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination
Article Snippet: .. Time-dependent monitoring of cells treated with LPP packaged with FAM-mRNA (LPP/FAM-mRNA) showed a delayed increase in fluorescent intensity, with a high intensity level reached 120 minutes after incubation , indicating the mRNA molecules exited endosomes and entered the cytosol successfully. ..

other:

Article Title: Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination
Article Snippet: DC2.4 served as the antigen presenting cells and mRNA molecules encoding the eGFP protein was applied to prepare the polyplex core.

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    TriLink mrna molecules
    Structure and characterization of lipopolyplex <t>mRNA</t> vaccine ( a ) Schematic view of the lipopolyplex mRNA vaccine. The vaccine is composed of a polyplex core assembled through electrostatic interaction between the positively charged <t>PbAE</t> polymer and the negatively charged mRNA molecule. The polyplex is encapsulated into a lipid shell. ( b ) Gel retardation assay on polyplex-mRNA binding. Samples were loaded in the following order: free mRNA, polyplex/mRNA with 10, 20, 30 and 40 (w/w). ( c–e ) TEM images of the empty liposomal shell (c), polyplex/mRNA core (w/w=20) (d), and lipopolyplex/mRNA core-shell structure (e). ( f–k ) eGFP expression in DC2.4 cells treated with mRNA-packaged particles. DC2.4 cells were treated with (f) PBS control, g) PbAE/eGFP mRNA core, h) EDOPC/DOPE-packaged PbAE/eGFP mRNA, i) DOTAP/Chol-packaged PbAE/eGFP mRNA, j) CHEMS/DOPE/R8-packaged PbAE/eGFP mRNA or k) protamine/eGFP mRNA core, and eGFP expression was detected under a fluorescent microscope 24 hours later. l) DC2.4 viability upon treatment with the different particles.
    Mrna Molecules, supplied by TriLink, used in various techniques. Bioz Stars score: 91/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrna molecules/product/TriLink
    Average 91 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    mrna molecules - by Bioz Stars, 2020-09
    91/100 stars
      Buy from Supplier

    Image Search Results


    Structure and characterization of lipopolyplex mRNA vaccine ( a ) Schematic view of the lipopolyplex mRNA vaccine. The vaccine is composed of a polyplex core assembled through electrostatic interaction between the positively charged PbAE polymer and the negatively charged mRNA molecule. The polyplex is encapsulated into a lipid shell. ( b ) Gel retardation assay on polyplex-mRNA binding. Samples were loaded in the following order: free mRNA, polyplex/mRNA with 10, 20, 30 and 40 (w/w). ( c–e ) TEM images of the empty liposomal shell (c), polyplex/mRNA core (w/w=20) (d), and lipopolyplex/mRNA core-shell structure (e). ( f–k ) eGFP expression in DC2.4 cells treated with mRNA-packaged particles. DC2.4 cells were treated with (f) PBS control, g) PbAE/eGFP mRNA core, h) EDOPC/DOPE-packaged PbAE/eGFP mRNA, i) DOTAP/Chol-packaged PbAE/eGFP mRNA, j) CHEMS/DOPE/R8-packaged PbAE/eGFP mRNA or k) protamine/eGFP mRNA core, and eGFP expression was detected under a fluorescent microscope 24 hours later. l) DC2.4 viability upon treatment with the different particles.

    Journal: Biomaterials

    Article Title: Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination

    doi: 10.1016/j.biomaterials.2017.02.019

    Figure Lengend Snippet: Structure and characterization of lipopolyplex mRNA vaccine ( a ) Schematic view of the lipopolyplex mRNA vaccine. The vaccine is composed of a polyplex core assembled through electrostatic interaction between the positively charged PbAE polymer and the negatively charged mRNA molecule. The polyplex is encapsulated into a lipid shell. ( b ) Gel retardation assay on polyplex-mRNA binding. Samples were loaded in the following order: free mRNA, polyplex/mRNA with 10, 20, 30 and 40 (w/w). ( c–e ) TEM images of the empty liposomal shell (c), polyplex/mRNA core (w/w=20) (d), and lipopolyplex/mRNA core-shell structure (e). ( f–k ) eGFP expression in DC2.4 cells treated with mRNA-packaged particles. DC2.4 cells were treated with (f) PBS control, g) PbAE/eGFP mRNA core, h) EDOPC/DOPE-packaged PbAE/eGFP mRNA, i) DOTAP/Chol-packaged PbAE/eGFP mRNA, j) CHEMS/DOPE/R8-packaged PbAE/eGFP mRNA or k) protamine/eGFP mRNA core, and eGFP expression was detected under a fluorescent microscope 24 hours later. l) DC2.4 viability upon treatment with the different particles.

    Article Snippet: PbAE/mRNA polyplex was prepared by mixing one volume of the PbAE polymer with two volumes of mRNA molecules (Trilink Biotechnologies, San Diego, CA).

    Techniques: Electrophoretic Mobility Shift Assay, Binding Assay, Transmission Electron Microscopy, Expressing, Microscopy

    Stimulation of DC antigen cross-presentation by the LPP/mRNA vaccine a ) Flow cytometry analysis on H-2k b -OVA 257–264 presentation. b ) Time-dependent IL-2 secretion by OVA-specific CD4 + and CD8 + T cells after co-incubation with post-treated BMDCs. B3Z: OVA-specific CD8 + T cell; DOBW: OVA-specific CD4 + T cell. c ) Time-dependent IL-2 secretion by OVA-specific CD4 + and CD8 + T cells after co-incubation with post-treated DC2.4 cells. d ) Comparison of IL-2 secretion by OVA-specific CD8 + T cells after co-incubation with DC2.4 cells pretreated with LPP/OVA mRNA or LPP/OVA protein.

    Journal: Biomaterials

    Article Title: Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination

    doi: 10.1016/j.biomaterials.2017.02.019

    Figure Lengend Snippet: Stimulation of DC antigen cross-presentation by the LPP/mRNA vaccine a ) Flow cytometry analysis on H-2k b -OVA 257–264 presentation. b ) Time-dependent IL-2 secretion by OVA-specific CD4 + and CD8 + T cells after co-incubation with post-treated BMDCs. B3Z: OVA-specific CD8 + T cell; DOBW: OVA-specific CD4 + T cell. c ) Time-dependent IL-2 secretion by OVA-specific CD4 + and CD8 + T cells after co-incubation with post-treated DC2.4 cells. d ) Comparison of IL-2 secretion by OVA-specific CD8 + T cells after co-incubation with DC2.4 cells pretreated with LPP/OVA mRNA or LPP/OVA protein.

    Article Snippet: DC2.4 served as the antigen presenting cells and mRNA molecules encoding the eGFP protein was applied to prepare the polyplex core.

    Techniques: Flow Cytometry, Cytometry, Incubation

    Preferential uptake of the lipopolyplex mRNA vaccine by dendritic cells (a) Flow cytometry analysis on GFP-positive cells after DC2.4, MDA-MB-231 and mDMEC cells were incubated with lipopolyplex/eGFP mRNA for 24 hours. (b) Bioluminescent image to detect luciferase expression in mice 48 hours after s.c. injection of LPP/Luc. Left: control mouse; right: LPP/Luc-treated mouse.

    Journal: Biomaterials

    Article Title: Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination

    doi: 10.1016/j.biomaterials.2017.02.019

    Figure Lengend Snippet: Preferential uptake of the lipopolyplex mRNA vaccine by dendritic cells (a) Flow cytometry analysis on GFP-positive cells after DC2.4, MDA-MB-231 and mDMEC cells were incubated with lipopolyplex/eGFP mRNA for 24 hours. (b) Bioluminescent image to detect luciferase expression in mice 48 hours after s.c. injection of LPP/Luc. Left: control mouse; right: LPP/Luc-treated mouse.

    Article Snippet: DC2.4 served as the antigen presenting cells and mRNA molecules encoding the eGFP protein was applied to prepare the polyplex core.

    Techniques: Flow Cytometry, Cytometry, Multiple Displacement Amplification, Incubation, Luciferase, Expressing, Mouse Assay, Injection

    Mechanism of cell entry ( a – h ) Images of DC2.4 cells treated with LPP/0.5 μg FAM-labeled eGFP mRNA for 4 hours in presence of (a) mock control, (b) amiloride, (c) chlorpromazine, (d) chloroquine, (e) genistein, (f) pimozide, (g) nocodazole, and (h) cytochalasin D. ( i ) Image J analysis on FAM-positive cells. ( j ) Time-dependent uptake of LPP/FAM-labeled eGFP mRNA by DC2.4 cells. Error bars represent the mean ± standard deviation of triplicate experiments.

    Journal: Biomaterials

    Article Title: Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination

    doi: 10.1016/j.biomaterials.2017.02.019

    Figure Lengend Snippet: Mechanism of cell entry ( a – h ) Images of DC2.4 cells treated with LPP/0.5 μg FAM-labeled eGFP mRNA for 4 hours in presence of (a) mock control, (b) amiloride, (c) chlorpromazine, (d) chloroquine, (e) genistein, (f) pimozide, (g) nocodazole, and (h) cytochalasin D. ( i ) Image J analysis on FAM-positive cells. ( j ) Time-dependent uptake of LPP/FAM-labeled eGFP mRNA by DC2.4 cells. Error bars represent the mean ± standard deviation of triplicate experiments.

    Article Snippet: DC2.4 served as the antigen presenting cells and mRNA molecules encoding the eGFP protein was applied to prepare the polyplex core.

    Techniques: Labeling, Standard Deviation